Arrakis Therapeutics Stock

arrakistx.comHealthcareFounded: 2015Funding to Date: $113.5MM

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA.

Register for Details

For more details on financing and valuation for Arrakis Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Arrakis Therapeutics.

Register Today

Team

Management Team

Daniel Koerwer
Chief Business Officer
Heather Lounsbury
Vice President of Business & Technical Operations
Jennifer Petter Ph.D
Co-Founder & Chief Scientific Officer
Rajesh Parekh Ph.D
Co-Founder & Board Member
Michael Gilman Ph.D
Chief Executive Officer & Chairman
Alan Walts Ph.D
Co-Founder & Board Member
James Barsoum Ph.D
Senior Vice President of Biology
Henri Termeer
Co-Founder

Board Members

Carolyn Green
Matthew Cohen Ph.D
Osage Venture Partners
Rajesh Parekh Ph.D
Alan Walts Ph.D
Jakob Loven Ph.D
Nextech Invest
Nikola Trbovic Ph.D
Pfizer Ventures
Colleen Cuffaro Ph.D
Canaan Partners
Elaine Jones Ph.D
Pfizer Ventures
Peter Worland Ph.D
Celgene
Richard Gaster MD
venBio
Michael Gilman Ph.D
Timothy Shannon MD
Canaan Partners

Other companies like Arrakis Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B